Malaysia's NPRA grants marketing approval for Yifan's innovative drug Ryzneuta®

Yifan Pharmaceutical announced that its controlling subsidiary, Evive Biotech Ltd., recently obtained marketing approval for Ryzneuta® (known in China as "Yilishu®") from Malaysia's National Pharmaceutical Regulatory Agency (NPRA). This milestone grants the Company's innovative biologic product, Yilishu®, the authorization for commercial sale in the Malaysian market.

Located in Southeast Asia, Malaysia boasts a per capita GDP of approximately US$11,649—on par with China's level—ranking third in the region and demonstrating strong economic growth momentum in recent years. As an active participant in the Belt and Road Initiative and a key member of the ASEAN Free Trade Area, Malaysia has engaged in extensive cooperation with China across multiple sectors.

According to industry projections, Malaysia's pharmaceutical market is expected to reach a total value of US$1.74 billion (approximately RM8.14 billion) by 2025, reflecting a compound annual growth rate (CAGR) of 4.87%. By 2029, the market size is projected to expand to US$2.1 billion (around RM9.83 billion). With over 50% of pharmaceuticals in Malaysia relying on imports, the country's healthcare market demonstrates significant growth potential.